# Targeting Cannabinoid Receptors to Regulate Blood Glucose and Weight > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-receptors-blood-glucose-regulation/ > **Published:** 2021-04-13T14:27:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:10-04:00 > **Clinical Summary:** Explore how cannabinoid receptors blood glucose regulation impacts body weight and potential obesity management strategies. --- ### Influence of Cannabinoid Receptor Deficiency on Parameters Involved in Blood Glucose Regulation in Mice In Summary The pancreas is the organ that produces insulin and its lesser known counterpart, glucagon, both of which are responsible for regulating blood sugar. The pancreas’ function, therefore, is implicated in regulation of the body weight and consequently, conditions such as obesity. The two [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), CB1 and CB2, are known to be expressed in pancreatic cells. Indeed, cannabinoids – compounds that can be produced naturally by our body, synthesized artificially, or extracted from the plant cannabis – have long been shown to influence the secretion of insulin and glucagon by the pancreas via these receptors. ​ However, it was not until recently that scientists demonstrated the impacts of CB1’s and CB2’s activities on blood glucose level and weight regulation by the pancreas. In particular, they found that in mice without pancreatic CB1 receptors, both blood sugar levels and body weights decreased compared to normal mice. In contrast, in mice without pancreatic [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), blood glucose levels were found to be elevated and body weights to increase compared to normal mice, especially in male animals. These insights can be translated into [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) approaches. For instance, a drug that blocks CB1 receptors’ function or one that activates [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/) in humans may lead to the same effects of decreasing body weight and therefore can represent an promising obesity management strategy. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Citral, a natural activator of the cannabinoid receptor type 2, can help combat pain and inflammatory conditions](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) Discover how natural compounds like citral activate [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) to reduce pain and inflammation. [Read More](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/) [Anti-Obesity Therapy with Peripheral CB1 Blockers: From Promise to Safe Practice](https://cedclinic.com/peripheral-cb1-blockers-obesity-therapy-safe-practice/) Explore the potential of peripheral CB1 blockers as a safe and effective anti-obesity therapy. [Learn More](https://cedclinic.com/peripheral-cb1-blockers-obesity-therapy-safe-practice/) [Neurological and neurodegenerative conditions, physical activities, and the endocannabinoid system – how might all these be linked?](https://cedclinic.com/endocannabinoid-system-neurological-disorders-link/) Understand the connections between the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), [neurological health](https://cedclinic.com/benzodiazepine-discontinuation-rates-medical-cannabis/), and physical activity. [Discover More](https://cedclinic.com/endocannabinoid-system-neurological-disorders-link/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Targeting%20Cannabinoid%20Receptors%20to%20Regulate%20Blood%20Glucose%20and%20Weight&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptors-blood-glucose-regulation%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptors-blood-glucose-regulation%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Targeting%20Cannabinoid%20Receptors%20to%20Regulate%20Blood%20Glucose%20and%20Weight%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-receptors-blood-glucose-regulation%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).